Remove Diabetes Remove Pharmaceutical Companies Remove Pharmacy Technician
article thumbnail

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Pharmacy Times

This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

In 2022, based upon a complaint filed by a pharmaceutical company, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. Based on this ruling, 505(b)(2) drugs that are not therapeutically interchangeable should be considered sole-source drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

7. Reflections on a Career in Pharmacy and Medicine with Dr. Steven Berk

The Physician Pharmacist

And I was working, I got a job in a pharmacy satellite at Erie County Medical Center, I don't know if you're familiar with so County Health Center in Buffalo working in a pharmacy satellite, my last year of pharmacy school, up in the ICUs. And one of the so I was a pharmacy technician at the time, I wasn't a pharmacist yet.

article thumbnail

8. The Entrepreneurial Life of Dr. Richard Harris, a Pharmacist, Physician, and Business Mastermind

The Physician Pharmacist

And I think it's so interesting that you jumped into pharmacy without having like any experience in the field like prior to like working in retail. It's also really interesting that you were interested in medical school since pretty much the first year of pharmacy school. So I think that's fascinating. It doesn't work like that.

article thumbnail

Is Belantamab Mafodotin Making a Comeback?

Pharmacy Times

4,5 DREAMM-7 In DREAMM-7, patients with RRMM who had received at least 1 prior line of therapy were randomized 1:1 to receive belantamab mafodotin plus bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies) and dexamethasone (BVd) compared with daratumumab (Darzalex; Johnson & Johnson), bortezomib, and dexamethasone (DVd).